Latin name: Provera

Pharmacological groups: Anti-hormonal and hormone antagonists. Estrogens, progestins, and their homologues and antagonists
The nosological classification (ICD-10): C50 Malignant neoplasm of breast cancer. C54 Malignant neoplasm of corpus uteri. C54.1 endometrium. C64 Malignant neoplasm of kidney, except renal pelvis.





Pharmacological action:

The active substance (INN) Medroxyprogesterone .

The use of Provera: Contraception, particularly in women of late reproductive age inoperable, recurrent and metastatic carcinoma of the endometrium and kidney (additional palliative therapy), hormone-dependent forms of recurrent breast cancer in postmenopausal period of women.

Inside – secondary amenorrhea, dysfunctional uterine bleeding, premenstrual syndrome, vasomotor symptoms of menopause, endometriosis, the diagnosis of primary and secondary amenorrhea, prevention and treatment of osteoporosis in postmenopauznom period (in combination with estrogen and calcium supplementation), prevention of endometrial changes in replacement therapy estrogen in postmenopausal women.
Contra-Provera: hypersensitivity, thrombophlebitis, thromboembolic syndrome or a history of stroke, liver disease, vaginal bleeding of unspecified etiology, pregnancy, breastfeeding (stop).

Side effects: Menstrual irregularities, thromboembolism, insomnia, irritability, drowsiness, fatigue, weakness, depression, dizziness, headache, edema, nausea, abdominal pain and abdominal discomfort, breast tenderness, galactorrhea, cervical erosion, hirsutism, alopecia , fever, weight change, moon face, osteoporosis, urticaria, pruritus, acne, anaphylaxis and anaphylactoid reactions.

Interaction: aminoglutethimide reduces plasma concentrations and reduces efficiency.

Dosage and administration: V / m, as a contraceptive and for the removal of vasomotor symptoms of menopause – 150 mg 1 time in 3 months, with endometriosis, 50 mg 1 time per week or 100 mg of 1 every 2 weeks course of at least 6 months.
B / B with endometrial cancer or kidney disease – 400-1000 mg weekly, while achieving clinical improvement – 400 mg 1 time per month.

Inside, in endometrial cancer or kidney disease – 200-600 mg / day for breast cancer – 400-1200 mg / day. For the prevention and treatment of osteoporosis in postmenopausal women – from 12-15 to 25 day of the month at 5-10 mg 1 time a day.

Precautions: The first method should be used only on the 5th day of normal menstrual period (guarantee of the absence of pregnancy). You must use an additional contraceptive method for 2 weeks after the first injection. Every three months we recommend an injection of the drug (increased reliability of contraception), when the cycle changes during the reception of required medical consultation. With dysfunctional uterine bleeding necessarily rule out uterine cancer, and other organic lesions. Suspicion for the development of thrombophilic states (thrombophlebitis, cerebrovascular disorders, pulmonary artery branches thromboembolism, renal thrombosis) require immediate repeal. Care must be taken for epilepsy, migraine, asthma, cardiac and renal failure, given the possible delay of the liquid. With care prescribe for patients with diabetes, depression.

Special instructions: The intake of medroxyprogesterone may change the results of laboratory tests (including sulfabromoftaleinovogo and other liver function tests) – reduction of steroids in plasma and urine (progesterone, estradiol, pregnandiol, testosterone, cortisol), gonadotropins, globulin, sex hormone binding, the level of T3, elevated levels of prothrombin, factors VII, VIII, IX, X.

The advantages of injectable contraceptive Provera:
    * High contraceptive efficacy;
    * As a result of contraception there is absolutely no need to worry;
    * Easy to use: Provera is suitable for those women who for one reason or another can not take a daily hormone pills;
    * Provera helps to significantly reduce the risk of inflammatory diseases of the genital organs and ectopic pregnancy;
    * Decrease the frequency of metabolic changes, as the drug does not pass through the liver;
    * Provera provides a therapeutic effect of endometriosis, premenstrual syndrome and menopausal syndrome, some of the menstrual cycle;
    * Provera reduces the intensity of menstruation and menstrual pain;
    * Provera may make breast-feeding women and women with high blood pressure, headaches;
    * Ease of use and privacy: invisible injection, and the fact of birth may be kept secret, that is for some women is extremely important.

First injection of a woman can be done in 3 – 5 days of the menstrual cycle. For those who want to use Provera after birth, the injection should be carried out within five days after delivery for breastfeeding mothers – only 6 weeks. During the first 2 weeks after the first injection of the drug should be used in addition to any non-hormonal contraceptive.
There can be subsequent injections made about once every three months exacted, then every 12 weeks and 5 days. Such regimes are due to the peculiarities of the drug and provide it with maximum efficiency. If for any reason, the injection was not made on time, every time, you must first make sure that the woman is not pregnant, and then "catch up". The next 14 days after the "check" our experts recommend the use of additional methods of contraception, with the exception of other hormones (best fit condom or spermicide).

Women who use Provera, you need to know what injection can be done only in a medical facility by a qualified doctor or nurse. The spot can not be massaged or rubbed, it is better after a couple of hours to spend in a relaxed atmosphere. During the life of the injectable contraceptive, you must strictly adhere to the deadlines, which gynecologists recommend our center to conduct a special calendar, which record the date made and the date of the next injection. There is also a need to make information about the menstrual cycle (duration, amount of bleeding, mood) and show them to your gynecologist.

Be the first to comment on "Medroxyprogesterone"

Leave a comment

Your email address will not be published.